Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Schedule of Cumulative Effect of Changes to Condensed Consolidated Balance Sheet for Adoption of ASC 606

The cumulative effect of changes made to the Condensed Consolidated Balance Sheet at January 1, 2018 for the adoption of ASC 606 were as follows (in thousands):

	Balance at December 31, 2017			Adjustments Due to ASC 606		Balance at January 1, 2018
Assets:
Accounts receivable	$	19,967		$	17,243	$	37,210
Prepaid expenses and other current assets		9,118			710		9,828
Other assets		1,760			573		2,333
	Balance at December 31, 2017			Adjustments Due to ASC 606		Balance at January 1, 2018
Liabilities:
Deferred revenue	$	2,212		$	156	$	2,368
Roche related-party deferred revenue		3,742			78		3,820
	Balance at December 31, 2017			Adjustments Due to ASC 606		Balance at January 1, 2018
Equity:
Accumulated deficit	$	(506,349	)	$	18,292	$	(488,057	)

Schedule of Impact of Adoption on Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet

In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on our Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet was as follows (in thousands):

	For the three months ended March 31, 2018
Revenue:	As  Reported Under ASC 606		Effect of Change Higher/(Lower)			Balances Without Adoption of ASC 606
Molecular information services	$	31,943	$	3,212		$	35,155
Related-party molecular information services from Roche		14,648		(374	)		14,274
Pharma research and development services		4,782		(3,923	)		859
Related-party pharma research and development services from Roche		1,467	—				1,467

	March 31, 2018
Assets:	As  Reported Under ASC 606			Effect of Change Higher/(Lower)			Balances Without Adoption of ASC 606
Accounts receivable	$	32,222		$	(14,008	)	$	18,214
Prepaid expenses and other current assets		13,003			(4,771	)		8,232
Other assets		2,225			(491	)		1,734
Liabilities:	As  Reported Under ASC 606			Effect of Change Higher/(Lower)			Balances Without Adoption of ASC 606
Deferred revenue	$	2,867		$	(179	)	$	2,688
Roche related-party deferred revenue		4,801			286			5,087
Equity:	As  Reported Under ASC 606			Effect of Change Higher/(Lower)			Balances Without Adoption of ASC 606
Accumulated deficit	$	(525,472	)	$	(19,377	)	$	(544,849	)